Roche outlined its plan to become an end-to-end oncology solutions provider, combining new acquisitions in diagnostics with sequencing and monitoring ambitions. Roche said it expects strong synergy from a pending $1.05 billion acquisition of PathAI, aimed at strengthening companion diagnostic development and earlier engagement in pharma partner programs. Roche also flagged a $595 million acquisition of Saga Diagnostics announced earlier, with Foundation Medicine positioning Pathlight MRD for expanded disease monitoring. Roche’s diagnostics day also included a new sequencing instrument, Axelios, described as a key enabler for molecular-based oncology testing across sites in the US and Europe.